Christy Jones Sells 1,998 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Christy Jones sold 1,998 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $9.95, for a total transaction of $19,880.10. Following the sale, the director directly owned 13,246 shares of the company’s stock, valued at $131,797.70. The trade was a 13.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beta Bionics Trading Down 0.8%

BBNX stock opened at $11.63 on Thursday. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The company has a market capitalization of $518.23 million, a P/E ratio of -7.70 and a beta of 3.29. The firm has a 50 day simple moving average of $10.66 and a 200-day simple moving average of $17.83.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. The business had revenue of $27.63 million during the quarter. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. On average, research analysts predict that Beta Bionics, Inc. will post -2.19 EPS for the current year.

Hedge Funds Weigh In On Beta Bionics

Several hedge funds and other institutional investors have recently modified their holdings of BBNX. Vanguard Group Inc. boosted its holdings in shares of Beta Bionics by 213.5% during the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock valued at $44,036,000 after acquiring an additional 1,509,217 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Beta Bionics during the fourth quarter valued at about $40,437,000. Eversept Partners LP raised its stake in shares of Beta Bionics by 108.6% during the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after purchasing an additional 736,576 shares in the last quarter. 12 West Capital Management LP bought a new stake in shares of Beta Bionics during the fourth quarter valued at about $17,520,000. Finally, Bruce & Co. Inc. bought a new stake in shares of Beta Bionics during the first quarter valued at about $5,518,000.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on BBNX shares. Weiss Ratings downgraded shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Bank of America reduced their price target on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a report on Monday, May 18th. The Goldman Sachs Group reduced their price target on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday. Robert W. Baird reduced their price target on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Finally, Leerink Partners reduced their price target on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Beta Bionics has a consensus rating of “Moderate Buy” and a consensus target price of $19.73.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.